Abstract
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
Original language | English |
---|---|
Article number | jiad052 |
Pages (from-to) | 586-590 |
Number of pages | 5 |
Journal | Journal of Infectious Diseases |
Volume | 228 |
Issue number | 5 |
Early online date | 1 Mar 2023 |
DOIs | |
Publication status | Published - 1 Sept 2023 |
Bibliographical note
Publisher Copyright:© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.